Search results for " Anti-Inflammatory Agents"

showing 10 items of 15 documents

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

2017

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, …

0301 basic medicine030204 cardiovascular system & hematologylaw.invention0302 clinical medicinec-reactive proteinRandomized controlled triallawCardiovascular Diseasemiddle ageddouble-blind methodantibodiesMyocardial infarctionhumansStrokeinterleukin-1betabiologyAntibodies MonoclonaldrugGeneral MedicineLipidAged; anti-inflammatory agents; antibodies; monoclonal; antibodies; monoclonal; humanized; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship; drug; double-blind method; female; humans; incidence; infections; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; strokestrokeAnti-Inflammatory AgentagedEditorialfemalemyocardial infarctionAtherosclerosiMonoclonalsecondary preventionHumanmedicine.drugmedicine.medical_specialtymonoclonalNeutropeniaAntibodies Monoclonal HumanizedInfectionsPlaceboaged; anti-inflammatory agents; antibodies monoclonal; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship drug; double-blind method; female; humans; incidence; infection; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; stroke; medicine (all)anti-inflammatory agentsdose-response relationshiplipids03 medical and health sciencesmaleInternal medicinemedicineneutropeniamedicine (all)Dose-Response Relationship Drugbusiness.industryAntiinflammatory Therapy Canakinumab for Atherosclerotic DiseaseC-reactive proteinmedicine.diseaseinfectioncardiovascular diseasesSurgeryCanakinumab030104 developmental biologyincidencebiology.proteinatherosclerosisbusinessNew England journal of medicine
researchProduct

Anti-Inflammatory Activity of Citrus bergamia Derivatives: Where Do We Stand?

2016

Inflammatory diseases affect a large portion of the worldwide population, and chronic inflammation is a major risk factor for several dangerous pathologies. To limit the side effects of both synthetic and biological anti-inflammatory drugs, the use of herbal medicines, nutraceuticals and food supplements has increased tremendously as alternative and/or complementary medicine to treat several pathologies, including inflammation. During the last decades, the biological properties of Citrus bergamia (bergamot) derivatives have obtained important scientific achievements, and it has been suggested their use in a context of a multitarget pharmacological strategy. Here, we present an overview of t…

0301 basic medicineCitrusnatural productsAnti-Inflammatory AgentsCitruantioxidant activityPharmaceutical SciencebergamotReviewPharmacologyAnalytical Chemistry0302 clinical medicinecomplementary and alternative medicinesDrug DiscoveryCitrus bergamiaeducation.field_of_studyTraditional medicineMedicine (all)3. Good healthAnti-Inflammatory AgentChemistry (miscellaneous)030220 oncology & carcinogenesisMolecular MedicineComplementary medicineHumanmedicine.drug_classHerbal MedicinePopulationContext (language use)Natural productAnti-inflammatoryPlant ExtractAntioxidant activity; Bergamot; Citrus bergamia; Complementary and alternative medicines; Flavonoids; Inflammation; Natural products; Anti-Inflammatory Agents; Citrus; Herbal Medicine; Humans; Inflammation; Plant Extracts; Organic Chemistrylcsh:QD241-44103 medical and health sciencesNutraceuticallcsh:Organic chemistrySettore MED/43 - Medicina LegaleBiological propertymedicineHumansPhysical and Theoretical ChemistryeducationAntioxidant activity Bergamot Citrus bergamia Complementary and alternative medicines Flavonoids Inflammation Natural products Medicine (all);Plant Extractsbusiness.industryOrganic Chemistry030104 developmental biologyComplementary and alternative medicineinflammationflavonoidsCitrus bergamiaFlavonoidSettore BIO/14 - FarmacologiabusinessMolecules
researchProduct

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

2020

AbstractCoronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct…

0301 basic medicinecoronavirusAnti-Inflammatory AgentsReview Article030204 cardiovascular system & hematologymedicine.disease_causelaw.inventioncovid190302 clinical medicineRandomized controlled triallawAntithromboticPandemicViralanticoagulationCoronavirusGlycosaminoglycansAnimals; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Betacoronavirus; Coronavirus Infections; Fibrinolytic Agents; Glycosaminoglycans; Hemostasis; Humans; Inflammation; Pandemics; Platelet Aggregation Inhibitors; Pneumonia Viral; Thrombosiscoronavirus 2immunomodulatorHematologyHeparinThrombosisantithrombinCoronavirus Infectionsmedicine.drugmedicine.medical_specialtyPneumonia Viralcoronavirus disease 2019 thrombosis inflammation fibrinolytic therapy anticoagulation immunomodulator antithrombin thrombomodulinAntiviral Agents03 medical and health sciencescoronavirus disease 2019BetacoronavirusFibrinolytic AgentsmedicineAnimalsHumansthrombosis COVID-19 coronavirusDosingIntensive care medicinePandemicsthrombosisInflammationHemostasisbusiness.industrySARS-CoV-2AnticoagulantsCOVID-19ThrombosisPneumoniathrombomodulinmedicine.diseaseReview articleCOVID-19 Drug Treatment030104 developmental biologyinflammationfibrinolytic therapybusinessPlatelet Aggregation InhibitorsThrombosis and haemostasis
researchProduct

Hop-derived fraction rich in beta acids and prenylflavonoids regulates the inflammatory response in dendritic cells differently from quercetin: unvei…

2021

Dendritic cells (DCs) represent a heterogeneous family of immune cells that link innate and adaptive immunity and their activation is linked to metabolic changes that are essential to support their activity and function. Hence, targeting the metabolism of DCs represents an opportunity to modify the inflammatory and immune response. Among the natural matrices, Humulus lupulus (Hop) compounds have recently been shown to exhibit immunomodulatory and anti-inflammatory activity. This study aimed to evaluate the ability of specific Hop fractions to modulate DCs metabolism after stimulation with lipopolysaccharide (LPS) by an untargeted metabolomics approach and compare their effect with flavonol …

LipopolysaccharideHop fractions Dendritic cells metabolomics analysis Nrf2/Nqo1 pathwayAnti-Inflammatory AgentsSuccinic AcidInbred C57BLMass SpectrometryProinflammatory cytokineHop (networking)chemistry.chemical_compoundMiceMetabolomicsImmune systemBone MarrowAnimalsMetabolomicsAnimals; Anti-Inflammatory Agents; Bone Marrow; Citrulline; Dendritic Cells; Disease Models Animal; Flavonoids; Humulus; Inflammation; Mass Spectrometry; Metabolomics; Mice; Mice Inbred C57BL; Plant Extracts; Purines; Pyrimidines; Quercetin; Succinic AcidHumulusFlavonoidsInflammationChemistryAnimalPlant ExtractsGeneral MedicineDendritic CellsAcquired immune systemSettore CHIM/08 - Chimica FarmaceuticaCell biologyMice Inbred C57BLDisease Models AnimalPyrimidinesPurinesDisease ModelsCitrullineTumor necrosis factor alphaQuercetinQuercetinFood ScienceFoodfunction
researchProduct

Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.

2016

IF 10.383; International audience; OBJECTIVES: Cancer may be a complication of inflammatory bowel disease (IBD) or its treatment. In elderly onset IBD patients the risk of malignancy is of particular concern. We studied this risk in a population-based cohort of elderly onset IBD patients.METHODS: In a French population-based cohort, we identified 844 patients aged >60 years at IBD diagnosis from 1988 to 2006, including 370 Crohn's disease (CD) and 474 ulcerative colitis (UC). We compared incidence of cancer among IBD patients with that observed in the French Network of population-based Cancer Registries (FRANCIM). Confidence interval (CI) was estimated assuming a Poisson-specific law for ra…

MESH: CarcinomaMaleNonmelanoma Skin-CancerInflammatory bowel disease0302 clinical medicineAdrenal Cortex HormonesAzathioprineMESH: IncidenceAge of OnsetAged 80 and overeducation.field_of_studyMESH: Middle AgedRheumatoid-ArthritisIncidenceGastroenterologyMESH: Follow-Up StudiesMESH: Anti-Inflammatory Agents Non-Steroidal3. Good health030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Immunosuppressive Agentsmedicine.medical_specialtyMESH: Age of OnsetMESH: Colitis Ulcerativedigestive systemMESH: Adrenal Cortex Hormones03 medical and health sciencesIntestinal NeoplasmsHumansCrohns-DiseaseeducationMESH: Intestinal NeoplasmsMESH: Protective FactorsMESH: AzathioprineAgedRetrospective StudiesMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphaMESH: Retrospective Studiesmedicine.diseaseMESH: Inflammatory Bowel DiseasesInflammatory Bowel Diseasesdigestive system diseasesLymphoproliferative DisordersMethotrexateMESH: Tumor Necrosis Factor-alphaColitis UlcerativeComplicationMESH: FemaleProspective Observational CohortTime FactorsMESH: RegistriesMESH: Proportional Hazards ModelsMaintenance TherapyMESH: Aged 80 and overMESH: Lymphoproliferative DisordersCrohn DiseaseMESH: Risk FactorsRisk FactorsNeoplasmsMESH: NeoplasmsRegistriesUlcerative-ColitisMesalamineMESH: AgedIncidence (epidemiology)Anti-Inflammatory Agents Non-SteroidalMetaanalysisMiddle AgedhumanitiesMESH: MethotrexateFemaleFranceFrench PopulationColorectal NeoplasmsImmunosuppressive AgentsMESH: Myeloproliferative DisordersPopulationColorectal-CancerIncreased RiskInternal medicinemedicineProportional Hazards ModelsMyeloproliferative DisordersHepatologybusiness.industryMESH: Time FactorsCarcinomaCancerRetrospective cohort study[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: MesalamineProtective FactorsMESH: MaleMESH: FranceAge of onsetbusinessMESH: Colorectal NeoplasmsFollow-Up StudiesThe American journal of gastroenterology
researchProduct

Physician–patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, pros…

2017

Background: Patients with multiple actinic keratoses (AKs) should be treated with field-directed therapy. Such treatments challenge patients’ adherence due to out-of-pocket costs, length of treatment and severity of local skin reactions (LSRs). Effective physician–patient communication (PPC) may buffer therapy-related distress, thus improving quality of life, treatment satisfaction and adherence. Objectives: We evaluated the interplay between PPC, LSR intensity (safety) and lesion clearance rates (effectiveness) on treatment satisfaction, quality of life and treatment adherence among patients with multiple AKs receiving topical field-directed therapies. Methods: In this observational, multi…

Male2708; infectious diseases; actinic keratosesDiclofenacActinictopical field‐directed therapyAnti-Inflammatory AgentsAntineoplastic AgentsAdministration CutaneousMedication AdherenceAdministration Cutaneous; Aged; Aged 80 and over; Anti-Inflammatory Agents Non-Steroidal; Antineoplastic Agents; Diclofenac; Diterpenes; Drug Eruptions; Female; Humans; Imiquimod; Italy; Keratosis Actinic; Longitudinal Studies; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Quality of Life; Communication; Medication Adherence; Patient Satisfaction; Physician-Patient Relationsactinic keratoses2708; Infectious Diseases80 and overHumansLongitudinal StudiesPatient Reported Outcome MeasuresProspective Studiesactinic keratoseAgedAged 80 and overPhysician-Patient RelationsImiquimodtreatmentCommunicationAnti-Inflammatory Agents Non-SteroidalKeratosisMiddle AgedKeratosis ActinicInfectious DiseasesCutaneousItalyPatient SatisfactionAdministrationQuality of LifeFemaleDrug EruptionsDiterpenesSettore MED/35 - MALATTIE CUTANEE E VENEREENon-Steroidal2708
researchProduct

Clinical and Biological Heterogeneity in Children with Moderate Asthma

2003

To evaluate the relationship between inflammatory markers and severity of asthma in children, the amount of interleukin-8 (IL-8) and granulocyte/macrophage colony-stimulating factor (GM-CSF) released by peripheral blood mononuclear cells, exhaled nitric oxide (FE NO) levels, p65 nuclear factor-kappaB subunit, and phosphorylated IkBalpha expression by peripheral blood mononuclear cells were assessed in six control subjects, 12 steroid-naives subjects with intermittent asthma, and 17 children with moderate asthma. To investigate their predictive value, biomarker levels were correlated with the number of exacerbations during a 18-month follow-up period. We found that GM-CSF release was higher …

MaleExacerbationAnti-Inflammatory AgentsCritical Care and Intensive Care MedicineSynaptotagminsMedicineChildSalmeterol XinafoateCalcium-Binding ProteinMembrane GlycoproteinsRespiratory diseaseNF-kappa Binflammatory markersBronchodilator AgentsAnti-Inflammatory AgentSynaptotagmin IBiomarker (medicine)FemaleMembrane GlycoproteinAndrostadienes; Anti-Inflammatory Agents; NF-kappa B; Leukocytes Mononuclear; Membrane Glycoproteins; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Synaptotagmins; Albuterol; Asthma; Child; Receptors Cell Surface; Nerve Tissue Proteins; Nitric Oxide; Synaptotagmin I; Calcium-Binding Proteins; Interleukin-8; Adolescent; Bronchodilator Agents; Male; Biological Markers; Femalemedicine.symptomHumanmedicine.drugPulmonary and Respiratory MedicineAdolescentNerve Tissue ProteinsReceptors Cell SurfaceInflammationNitric OxidePeripheral blood mononuclear cellFluticasone propionateHumansAlbuterolBronchodilator AgentAsthmaAndrostadienefluticasone propionatebusiness.industryCalcium-Binding ProteinsInterleukin-8Granulocyte-Macrophage Colony-Stimulating Factormedicine.diseaseSynaptotagminAsthmaAndrostadienesasthma; inflammatory markers; fluticasone propionateNerve Tissue ProteinBiological MarkerExhaled nitric oxideImmunologyLeukocytes MononuclearFluticasonebusinessBiomarkersAmerican Journal of Respiratory and Critical Care Medicine
researchProduct

Safety and efficacy of non-steroidal anti-inflammatory drugs to reduce ileus after colorectal surgery

2019

Ileus is common after elective colorectal surgery, and is associated with increased adverse events and prolonged hospital stay. The aim was to assess the role of non-steroidal anti-inflammatory drugs (NSAIDs) for reducing ileus after surgery.A prospective multicentre cohort study was delivered by an international, student- and trainee-led collaborative group. Adult patients undergoing elective colorectal resection between January and April 2018 were included. The primary outcome was time to gastrointestinal recovery, measured using a composite measure of bowel function and tolerance to oral intake. The impact of NSAIDs was explored using Cox regression analyses, including the results of a c…

Malerenal failureTime Factorsmedicine.medical_treatmentAdult; Aged; Anti-Inflammatory Agents Non-Steroidal; Elective Surgical Procedures; Female; Humans; Ileus; Kaplan-Meier Estimate; Male; Middle Aged; Patient Safety; Postoperative Care; Postoperative Complications; Proportional Hazards Models; Prospective Studies; Recovery of Function; Time Factors; Treatment Outcome; Colectomy; ProctectomyAnti-Inflammatory Agentscolorectal surgery; ileus; non-steroidal anti-inflammatory drugs; NSAIDSKaplan-Meier Estimate030230 surgeryTumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]0302 clinical medicinePostoperative ComplicationsProspective StudiesProspective cohort studyColectomyColorectalColectomyRISKProctectomyHazard ratioAnti-Inflammatory Agents Non-SteroidalAcute kidney injuryMiddle AgedColorectal surgeryNSAIDTreatment OutcomeElective Surgical Procedures030220 oncology & carcinogenesisFemalePatient SafetyNon-SteroidalCohort studyAdultcolorectal Surgery ileus non-steroidal anti-inflammatory drugsmedicine.medical_specialtyIleusNon‐steroidal anti‐inflammatory drugs. NSAIDs. Postoperative ileus. Colorectal surgery.ACUTE KIDNEY INJURYanti-inflammatory agents03 medical and health sciencesIleusInternal medicinemedicineHumansAdverse effectAgedProportional Hazards Modelsnon-steroidal anti-inflammatory drugs - ileus - colorectal surgeryPostoperative Carebusiness.industryRecovery of Functionmedicine.diseaseSettore MED/18 - Chirurgia Generalecolorectal cancer.Surgerycolorectal surgerybusiness
researchProduct

Atypical presentation of anti-N-methyl-D-aspartate receptor encephalitis: two case reports

2017

Abstract Background Anti-N-methyl-D-aspartate receptor encephalitis is a rare autoimmune disease characterized by severe neurological and psychiatric symptoms and a difficult diagnosis. The disease is often secondary to a neoplastic lesion, seldom diagnosed years later. Psychiatric symptoms are prevalent in adults; neurologic symptoms are more evident in children, who typically present primarily with neurological symptoms. To the best of our knowledge, the association with juvenile idiopathic arthritis has not been described. Case presentation We report the cases of two caucasian girls with an atypical presentation. The first patient was an 8-year-old girl with normal psychomotor developmen…

PediatricsPathologyChoreiform movementAnti-Inflammatory AgentsArthritislcsh:MedicineCase ReportDisease0302 clinical medicinePrednisoneChildOvarian Neoplasms030219 obstetrics & reproductive medicineMedicine (all)Remission InductionTeratomaImmunoglobulins IntravenousGeneral MedicineMagnetic Resonance ImagingTreatment OutcomeMethylprednisoloneFemaleHip JointTeratomamedicine.symptomEncephalitismedicine.drugmedicine.medical_specialtyAdolescentAnti-N-methyl-D-aspartate receptor encephalitis; Chorea; Juvenile idiopathic arthritis; Psychiatric symptoms; Speech disorders; Teratoma; Medicine (all)Methylprednisolone03 medical and health sciencesJuvenile idiopathic arthritiChoreaPsychiatric symptomsmedicineHumansImmunologic FactorsAnti-N-methyl-D-aspartate receptor encephalitis; Chorea; Juvenile idiopathic arthritis; Psychiatric symptoms; Speech disorders; TeratomaAnti-N-methyl-D-aspartate receptor encephalitis; Chorea; Juvenile idiopathic arthritis; Psychiatric symptoms; Speech disorders; Teratoma; Adolescent; Anti-Inflammatory Agents; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Arthritis Infectious; Child; Female; Hip Joint; Humans; Immunoglobulins Intravenous; Immunologic Factors; Magnetic Resonance Imaging; Methylprednisolone; Ovarian Neoplasms; Remission Induction; Teratoma; Treatment Outcome; Medicine (all)Speech disorderSpeech disordersArthritis InfectiousPsychiatric symptombusiness.industrylcsh:RChoreaJuvenile idiopathic arthritismedicine.diseaseAnti-N-methyl-D-aspartate receptor encephalitisbusiness030217 neurology & neurosurgeryAnti-N-methyl-D-aspartate receptor encephaliti
researchProduct

Impact of long-term treatment with inhaled corticosteroids and bronchodilators on lung function in a patient with post-infectious bronchiolitis oblit…

2016

Post-infectious bronchiolitis obliterans (PIBO) is a small airways disease characterized by fixed airflow limitation. Therefore, inhaled bronchodilators and corticosteroids are not recommended as maintenance therapy options. The management of PIBO currently consists only of close monitoring of affected patients, aimed at the prevention and early treatment of pulmonary infections. In recent years, there has been an increase in the incidence of PIBO in the pediatric population. Patients with PIBO are characterized by a progressive decline in lung function, accompanied by a decrease in overall functional capacity. Here, we report the case of a relatively young man diagnosed with PIBO and follo…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyLong term treatmentmedicine.drug_classmedicine.medical_treatmentBronchiolitis obliteransInhaled corticosteroidsAnti-inflammatory agents/ therapeutic useCase ReportMuscarinic antagonists/therapeutic use03 medical and health sciences0302 clinical medicineAnti-inflammatory agents/therapeutic useBronchodilatormedicinePulmonary rehabilitation030212 general & internal medicineBronchiolitis obliterans/therapyLung functionGynecologylcsh:RC705-779Administration inhalationinhalationbusiness.industrylcsh:Diseases of the respiratory systemmedicine.diseaseAdministration inhalation; Adrenergic beta-2 receptor antagonists/therapeutic use; Anti-inflammatory agents/ therapeutic use; Bronchiolitis obliterans/therapy; Infection/complications; Lung diseases/rehabilitation; Muscarinic antagonists/therapeutic use; Pulmonary and Respiratory MedicineLung diseases/rehabilitation030228 respiratory systemPhysical performanceInfection/complicationAnesthesiaInfection/complicationsAdministrationbusinessAdrenergic beta-2 receptor antagonists/therapeutic usePediatric populationJornal Brasileiro de Pneumologia
researchProduct